Articles tagged with “ai-in-pharma”

This analysis examines AI in the pharmaceutical supply chain, detailing machine learning applications for demand forecasting, procurement, and logistics.

Analyze the role of AI in pharma and biotech. Learn how machine learning is applied to drug discovery and clinical trials through industry case studies.

Examine the integration of AI in pharmaceutical CMC submissions and process analytics. Review QbD frameworks, regulatory guidelines, and manufacturing outcomes.

Examine Bristol Myers Squibb's Predict First strategy for drug discovery. Learn how BMS integrates AI to augment scientific decision-making and R&D efficiency.

Examine Sanofi's enterprise AI strategy to understand what AI at scale means in pharma. Learn how AI is integrated across biopharma R&D and manufacturing.

Review 10 essential AI tools for pharmaceutical R&D in 2026. This report details platforms for protein structure, generative design, and clinical modeling.

Explore FDA Structured Product Labeling (SPL) standards, current automation challenges, and how AI integration optimizes pharmaceutical regulatory workflows.

Analyze the life sciences software market projected to reach $45B by 2026. Examine AI trends, key segments, and five structural gaps hindering growth.

Analyze AI integration in pharma IT architecture, from R&D to supply chain. Review key data on MLOps, clinical trial efficiency, and FDA guidance.

Analyze the build vs buy AI decision in pharma. Compare costs, risks, and time-to-value for R&D and commercial teams to guide strategic investment.

Explore key strategies for accelerating pharma regulatory submissions. Learn about expedited pathways, process redesign, and the role of AI in shortening drug a

Explore key challenges in pharmaceutical regulatory submissions, from legacy eCTD issues and CMC gaps to the rise of AI and structured data for faster drug appr

Analysis of how Large Language Models (LLMs) automate clinical evidence collection for HTA economic dossiers. Covers systematic reviews, data extraction, and ch

Navigate FDA 21 CFR Part 11 for AI systems. This article details compliance strategies for validation, audit trails, and data integrity in regulated GxP setting

A comprehensive analysis of how data quality and data culture are foundational to AI success in pharmaceutical and life sciences organizations, covering assessment frameworks, governance models, regulatory compliance, and practical implementation roadmaps.

Explore a 2026 ROI analysis of Quality 4.0 in pharma manufacturing. Learn how technologies like AI & digital twins drive up to 45% cost savings and 40% capacity

Learn to build an AI-powered competitive intelligence stack for biotech in 2026. Covers data sources, NLP/ML methods, generative AI, agentic workflows, EU AI Act compliance, and use cases for R&D strategy.

Learn how AI, LLMs, and agentic AI can build a "Second Brain" for pharma R&D. Updated for 2026 with GraphRAG benchmarks, FDA AI guidance, and enterprise deployment patterns for searchable institutional memory in drug discovery.

Learn about Causaly Pipeline Graph and Agentic Research, AI platforms integrating competitive intelligence and knowledge graphs for pharma R&D. Updated April 2026 with market data, FDA guidance, and platform evolution.

Explore how AI impacts Good Documentation Practice (GDocP) and ALCOA+ principles in life sciences. Updated with the 2026 joint FDA-EMA 10 Guiding Principles, EU AI Act implementation timeline, and the EMA's first AI qualification opinion. Learn about efficiency gains, data integrity risks, and regulatory compliance strategies.

An analysis of leading pharmaceutical consulting firms in 2026, from global strategy to specialized AI boutiques. Review key services, $30B+ market data, AI trends, and firm rankings.

An in-depth analysis of the leaders in pharma digital transformation, examining the strategies of companies like AstraZeneca, Roche, Pfizer, Eli Lilly, and Sanofi with AI, generative AI, and cloud technologies — updated with 2025-2026 developments including Lilly's $1B NVIDIA AI lab and FDA AI guidance.

Explore our 2025 analysis of the top 25 pharmaceutical companies by AI patent filings. Learn who leads in AI R&D, key technology areas, and strategic trends.

Updated 2026: Learn what NVIDIA BioNeMo is and how it accelerates drug discovery. This guide explains its components, latest models (RNAPro, ReaSyn v2), the $1B Lilly partnership, and deployment for generative AI in biopharma.

Explore the technical architecture of RLHF for drug discovery. Learn how reward models and policy optimization align generative AI with expert chemist feedback, with 2025-2026 clinical validation data.

Learn about the EU AI Act's impact on pharma. Updated for 2026 with the Digital Omnibus proposal, GPAI Code of Practice, and revised Product Liability Directive. Includes risk classification, compliance steps, flowchart & SOP starter kit.

Our 2025 report analyzes the critical AI skills gap in the pharmaceutical industry, detailing the talent shortage with data and exploring key solutions.

An in-depth analysis of Merck's GPTeal platform and expanding AI strategy. Covers the KERMT drug discovery model, Mayo Clinic partnership, CSR automation results, and enterprise-scale LLM deployment across pharma R&D.

An in-depth case study of AstraZeneca's ChatGPT and generative AI implementation, updated for 2026. Covers enterprise strategy, R&D use cases, self-healing supply chains, and agentic AI adoption.